Also trades as: 4552.T (JPX) · $vol 2M
JCRRF OTC
JCR Pharmaceuticals Co., Ltd.
1W: +10.1%
1M: +8.1%
3M: +14.7%
YTD: -24.2%
1Y: +inf%
3Y: -65.0%
5Y: -86.2%
$3.60
+0.27 (+8.11%)
Weekly Expected Move ±5.2%
$3
$3
$4
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$109.2B
+4.2% ▲
5Y CAGR: +8.2%
Total Liabilities
$61.9B
+7.8% ▲
5Y CAGR: +11.9%
Shareholders Equity
$47.2B
+0.4% ▲
5Y CAGR: +4.2%
Cash & Investments
$14.1B
+6.8% ▲
5Y CAGR: -11.7%
Total Debt
$54.2B
+42.3% ▲
5Y CAGR: +24.5%
Net Debt
$40.1B
+61.1% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $30.7B | $13.3B | $18.8B | $13.2B | $14.1B |
| Short-Term Investments | $244M | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $31.0B | $13.3B | $18.8B | $13.2B | $14.1B |
| Net Receivables | $15.6B | $11.1B | $14.9B | $12.2B | $14.3B |
| Inventory | $14.6B | $18.5B | $20.9B | $21.8B | $24.2B |
| Other Current Assets | $990M | $4.9B | $3.0B | $3.9B | $3.5B |
| Total Current Assets | $62.2B | $47.8B | $57.6B | $51.1B | $56.1B |
| Property, Plant & Equip. | $26.8B | $32.7B | $30.0B | $37.4B | $39.5B |
| Goodwill & Intangibles | $3.0B | $3.7B | $3.5B | $3.0B | $2.6B |
| Long-Term Investments | $2.8B | $9.4B | $9.1B | $10.4B | $7.9B |
| Other Non-Current Assets | $0 | $0 | $2.0B | $0 | $691M |
| Total Non-Current Assets | $34.9B | $47.1B | $44.6B | $53.8B | $53.2B |
| Total Assets | $97.1B | $94.9B | $102.2B | $104.9B | $109.2B |
| — Liabilities — | |||||
| Accounts Payable | $1.3B | $1.6B | $890M | $590M | $526M |
| Short-Term Debt | $15.2B | $17.3B | $8.9B | $26.1B | $42.0B |
| Deferred Revenue | $12.1B | $3.9B | $1.7B | $0 | $0 |
| Other Current Liabilities | $24.6B | $15.8B | $15.9B | $14.2B | $3.8B |
| Total Current Liabilities | $42.1B | $35.8B | $30.1B | $44.0B | $48.1B |
| Long-Term Debt | $3.0B | $5.5B | $14.3B | $12.1B | $12.2B |
| Other Non-Current Liab. | $1.0B | $1.2B | $1.3B | $1.4B | $1.5B |
| Total Non-Current Liabilities | $4.0B | $6.8B | $15.6B | $13.4B | $13.7B |
| Total Liabilities | $46.0B | $42.5B | $45.8B | $57.4B | $61.9B |
| — Equity — | |||||
| Common Stock | $9.1B | $9.1B | $9.1B | $9.1B | $9.1B |
| Retained Earnings | $33.2B | $34.3B | $37.3B | $31.2B | $31.4B |
| Accumulated OCI | $0 | $1.4B | $2.4B | $1.5B | $1.2B |
| Total Stockholders Equity | $50.9B | $52.2B | $56.2B | $47.0B | $47.2B |
| Total Liabilities & Equity | $97.1B | $94.9B | $102.2B | $104.5B | $108.8B |
| — Key Metrics — | |||||
| Total Debt | $18.1B | $22.8B | $23.3B | $38.1B | $54.2B |
| Net Debt | -$12.6B | $9.5B | $4.5B | $24.9B | $40.1B |
| Total Investments | $3.0B | $9.4B | $9.1B | $10.4B | $7.9B |